Xu Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xu Zheng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Michio M. Kawano
Bio-Signal Analysis, Graduate School of Medicine, Yamaguchi Univ., Ube, Japan
3 shared publications- Hideaki Ishikawa
Research and Development Division of Sea Act, Sea Act CO., LTD, 2-17-8 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan
2 shared publications Jie Huang
Second Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China
2 shared publicationsKen-Ichiro Otsuyama
Department of Bio-signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Japan
2 shared publications- Naohiro Tsuyama
Department of Radiation Life Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan
2 shared publications - Saeid Abroun
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 shared publications
Latest Publications
- 21 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (3) , 1274-1289
Panax notoginseng Saponins Prevents Atherosclerosis and Reverse Steroid‐Resistance in Lupus Nephritis via Promoting the “ M2 ‐Polarization of Macrophages— PPARγ ” Positive Regulation
Lupus nephritis (LN) is a severe autoimmune disease often complicated by steroid resistance (SR), leading to treatment failure and poor prognosis like atherosclerosis (AS). Our study found that Panax notoginseng saponins (PNS) improve lipid metabolism and prevent AS in steroid‐resistant LN by up‐regulating PPARγ, though mechanisms are unclear. Recent research highlights the roles of macrophages, with M1 Mø promoting inflammation and M2 Mø providing protection, as PPARγ influences Mø's polarization, linking it to inflammation and M2 polarization, necessitating further investigation. Therefore, we conduct this study to investigate the regulatory effect of PNS on the “Mø M2 polarization‐PPARγ” positive regulation, endeavoring to elucidate its therapeutic potential of delaying AS and reversing SR in LN. PPARγ expression in polarized Mø was measured via PCR and WB, while M1/M2 biomarkers and cytokines, influenced by PPARγ modulation, were assessed using flow cytometry and ELISA. In mouse Mø treated with PNS, IL‐4, or both, PPARγ and cytokines were measured. ICR and MRL/lpr mice were used to establish an in vivo SR model to confirm PNS's role in M2 polarization of Mø and AS protection by analyzing blood lipid levels, iNOS, Lp(a), and apoptosis rates through WB, immunohistochemistry, HE‐staining, and TUNEL. PNS's efficacy in renal protection and SR reversal was evaluated through Scr, BUN, urine protein, renal pathology, and P‐gp; MDR1 expression was assessed via biochemical detection, HE‐staining, flow cytometry, and WB. This study confirmed that PNS upregulates PPARγ and promotes M2 polarization, improving abdominal aorta pathology and delaying AS. It also enhances renal function and reverses SR by reducing P‐gp and MDR1. This study shows that PNS promotes Mø polarization to M2 and enhances PPARγ expression, effectively preventing AS, improving renal function, and reversing SR in LN, offering insights for LN treatment and expanding PNS's therapeutic benefits for future research.
- 21 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (3) , 1274-1289
Panax notoginseng Saponins Prevents Atherosclerosis and Reverse Steroid‐Resistance in Lupus Nephritis via Promoting the “ M2 ‐Polarization of Macrophages— PPARγ ” Positive Regulation
Lupus nephritis (LN) is a severe autoimmune disease often complicated by steroid resistance (SR), leading to treatment failure and poor prognosis like atherosclerosis (AS). Our study found that Panax notoginseng saponins (PNS) improve lipid metabolism and prevent AS in steroid‐resistant LN by up‐regulating PPARγ, though mechanisms are unclear. Recent research highlights the roles of macrophages, with M1 Mø promoting inflammation and M2 Mø providing protection, as PPARγ influences Mø's polarization, linking it to inflammation and M2 polarization, necessitating further investigation. Therefore, we conduct this study to investigate the regulatory effect of PNS on the “Mø M2 polarization‐PPARγ” positive regulation, endeavoring to elucidate its therapeutic potential of delaying AS and reversing SR in LN. PPARγ expression in polarized Mø was measured via PCR and WB, while M1/M2 biomarkers and cytokines, influenced by PPARγ modulation, were assessed using flow cytometry and ELISA. In mouse Mø treated with PNS, IL‐4, or both, PPARγ and cytokines were measured. ICR and MRL/lpr mice were used to establish an in vivo SR model to confirm PNS's role in M2 polarization of Mø and AS protection by analyzing blood lipid levels, iNOS, Lp(a), and apoptosis rates through WB, immunohistochemistry, HE‐staining, and TUNEL. PNS's efficacy in renal protection and SR reversal was evaluated through Scr, BUN, urine protein, renal pathology, and P‐gp; MDR1 expression was assessed via biochemical detection, HE‐staining, flow cytometry, and WB. This study confirmed that PNS upregulates PPARγ and promotes M2 polarization, improving abdominal aorta pathology and delaying AS. It also enhances renal function and reverses SR by reducing P‐gp and MDR1. This study shows that PNS promotes Mø polarization to M2 and enhances PPARγ expression, effectively preventing AS, improving renal function, and reversing SR in LN, offering insights for LN treatment and expanding PNS's therapeutic benefits for future research.
- Open Access
- 24 June 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (6)
The Current Trends in Research on Panax notoginseng Saponins
Panax notoginseng (Burk.) F. H. Chen, an esteemed herbal medicine in traditional Chinese medicine (TCM), is notable for its bioactive compounds, particularly Panax notoginseng saponins (PNS), which exhibit a diverse range of pharmacological effects, including anti-inflammatory, antioxidant, anti-apoptotic, and anti-tumor properties, thereby providing significant therapeutic benefits in the context of cardiovascular, nervous system, and immune disorders. The aim of this study was to elucidate the contemporary research trends associated with PNS and to provide a roadmap for future investigative directions. A comprehensive review of the literature on PNS published from 2000 to 2024 was conducted utilizing the Web of Science Core Collection (WoSCC) database, supplemented by analytical tools such as VOSviewer and CiteSpace, which facilitated the identification of several emergent research hotspots, namely “endoplasmic reticulum stress,” “gut microbiota,” “pyroptosis,” “ferroptosis,” and “network pharmacology.” The findings of this groundwork not only highlight the dynamic interest surrounding PNS within the scientific community but also delineate specific thematic avenues that warrant further exploration, thereby fostering future research initiatives aimed at fully elucidating the multifaceted therapeutic potential of PNS in various pathological contexts.
- 24 June 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (6)
Open AccessThe Current Trends in Research on Panax notoginseng Saponins
Panax notoginseng (Burk.) F. H. Chen, an esteemed herbal medicine in traditional Chinese medicine (TCM), is notable for its bioactive compounds, particularly Panax notoginseng saponins (PNS), which exhibit a diverse range of pharmacological effects, including anti-inflammatory, antioxidant, anti-apoptotic, and anti-tumor properties, thereby providing significant therapeutic benefits in the context of cardiovascular, nervous system, and immune disorders. The aim of this study was to elucidate the contemporary research trends associated with PNS and to provide a roadmap for future investigative directions. A comprehensive review of the literature on PNS published from 2000 to 2024 was conducted utilizing the Web of Science Core Collection (WoSCC) database, supplemented by analytical tools such as VOSviewer and CiteSpace, which facilitated the identification of several emergent research hotspots, namely “endoplasmic reticulum stress,” “gut microbiota,” “pyroptosis,” “ferroptosis,” and “network pharmacology.” The findings of this groundwork not only highlight the dynamic interest surrounding PNS within the scientific community but also delineate specific thematic avenues that warrant further exploration, thereby fostering future research initiatives aimed at fully elucidating the multifaceted therapeutic potential of PNS in various pathological contexts.
- 1 January 2022
- Published by Elsevier in Phytomedicine
- Vol. 95, 153861
Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- 1 January 2022
- Published by Elsevier in Phytomedicine
- Vol. 95, 153861
Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- Open Access
- 16 November 2005
- Published by American Society of Hematology in Blood
- Vol. 106 (11) , 5054
The Loss of CD19 in Myeloma Cells Contributes to the Escape from FcγRII-Mediated Growth Suppression.
CD19 expression is specifically lost on human myeloma cells by the loss of Pax-5 gene expression, while normal plasma cells do express CD19. In order to examine the biological meaning of the loss of CD19 expression in human myeloma cells, we have generated CD19 transfectants of human myeloma cell lines (U266 and KMS-5 cells) and of a human non-myeloma erythroleukemia cell line (K562) and compared their proliferation and survival with those of their corresponding parent or only vector-transfected cells in the serum-containing or serum-free medium (supplemented with BSA and transferrin) in vitro. Exogenous introduction of CD19 expression markedly suppressed the proliferation of these cells in the serum-containing medium, but there existed less suppressive effect of CD19 introduction in serum-free culture. Among the serum components, we focused on the IgG and examined the effect of addition of high concentration of IgG or addition of anti-CD32 (FcγRII) antibody in this serum-free medium. Addition of high concentration of IgG induced the marked suppression of CD19 transfectants more than that of parent or mock transfectants, and furthermore, stimulation with anti-CD32 antibody also showed the suppression of CD19 transfectants more than that of the mock cells. We also confirmed that primary myeloma cells as well as myeloma cell lines predominantly expressed FcγRII(CD32), but not FcγRI(CD64) or FcγRIII(CD16), and were found to express FcγRIIB gene by RT-PCR. Furthermore, the treatment with anti-CD32 antibody induced the tyrosine phosphorylation of CD32b in the CD19+ cells more than that in CD19- mock cells, and also the phosphorylation of SHIP, but not SHP-1 or SHP-2 was enhanced in CD19+ cells. Therefore, these data suggest that myeloma cells as well as plasma cells or B cells express FcγRII(CD32), and CD19- myeloma cells are less sensitive to the FcγRII-mediated growth suppression than CD19+ normal plasma cells or B cells.
- 16 November 2005
- Published by American Society of Hematology in Blood
- Vol. 106 (11) , 5054
Open AccessThe Loss of CD19 in Myeloma Cells Contributes to the Escape from FcγRII-Mediated Growth Suppression.
CD19 expression is specifically lost on human myeloma cells by the loss of Pax-5 gene expression, while normal plasma cells do express CD19. In order to examine the biological meaning of the loss of CD19 expression in human myeloma cells, we have generated CD19 transfectants of human myeloma cell lines (U266 and KMS-5 cells) and of a human non-myeloma erythroleukemia cell line (K562) and compared their proliferation and survival with those of their corresponding parent or only vector-transfected cells in the serum-containing or serum-free medium (supplemented with BSA and transferrin) in vitro. Exogenous introduction of CD19 expression markedly suppressed the proliferation of these cells in the serum-containing medium, but there existed less suppressive effect of CD19 introduction in serum-free culture. Among the serum components, we focused on the IgG and examined the effect of addition of high concentration of IgG or addition of anti-CD32 (FcγRII) antibody in this serum-free medium. Addition of high concentration of IgG induced the marked suppression of CD19 transfectants more than that of parent or mock transfectants, and furthermore, stimulation with anti-CD32 antibody also showed the suppression of CD19 transfectants more than that of the mock cells. We also confirmed that primary myeloma cells as well as myeloma cell lines predominantly expressed FcγRII(CD32), but not FcγRI(CD64) or FcγRIII(CD16), and were found to express FcγRIIB gene by RT-PCR. Furthermore, the treatment with anti-CD32 antibody induced the tyrosine phosphorylation of CD32b in the CD19+ cells more than that in CD19- mock cells, and also the phosphorylation of SHIP, but not SHP-1 or SHP-2 was enhanced in CD19+ cells. Therefore, these data suggest that myeloma cells as well as plasma cells or B cells express FcγRII(CD32), and CD19- myeloma cells are less sensitive to the FcγRII-mediated growth suppression than CD19+ normal plasma cells or B cells.
- Open Access
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 2458
DHEA Can Inhibit the Proliferation of Myeloma Cells and the IL-6 Production of Bone Marrow Mononuclear Cells from the Myeloma Patients.
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 2458
Open AccessDHEA Can Inhibit the Proliferation of Myeloma Cells and the IL-6 Production of Bone Marrow Mononuclear Cells from the Myeloma Patients.
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.
- Open Access
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 4843
Roles of CD19 Molecules That Suppress Proliferation and Induce Apoptosis in Human Myeloma Cells.
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.
- 16 November 2004
- Published by American Society of Hematology in Blood
- Vol. 104 (11) , 4843
Open AccessRoles of CD19 Molecules That Suppress Proliferation and Induce Apoptosis in Human Myeloma Cells.
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.